Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma

Inclusion Criteria: * written informed consent * male or female subjects aged ≥ 18 to 75 years at time of screening * female if she is of non-childbearing potential, or of childbearing potential and willing to use specific barrier methods specified in protocol * confirmation of asthma * symptoms consistent with a diagnosis of asthma that is poorly controlled with an inhaled corticosteroid as determined by an Asthma Control Questionnaire (ACQ) score ≥ 1.5 * requirement for treatment with high dose daily fluticasone and at least one other agent for the treatment of asthma not specifically excluded in the protocol * requirement for \>/= 3% eosinophils in induced sputum at Screening Exclusion Criteria: * a clinically important event that would interfere with study schedule or procedure or compromise subject safety * a diagnosis of hypereosinophilic syndrome * an underlying lung disorder * a current smoker * use of systemic immunosuppressive agents within 6 months of study * current use of systemic corticosteroids * received attenuated live attenuated vaccines within three months prior to study entry * expected to be poorly compliant with study drug, procedures, visits * aggravating factors that are inadequately controlled * participation in any investigational drug or device study within 30 days prior to study entry * participation in biologics study within 3 months prior to study entry * receipt of anti-human interleukin-5 (hIL-5) antibody within 6 months of study entry * female subjects who are pregnant or nursing * concurrent infection or disease that may preclude assessment of eosinophilic esophagitis * concurrent immunodeficiency (human immunodeficiency \[HIV\], or acquired immunodeficiency syndrome \[AIDS\] or congenital immunodeficiency). * current suspected drug and/or alcohol abuse